Astellas' darexaban in ACS – value far above RUBY-1?
This article was originally published in Scrip
Executive Summary
Astellas's investigational Factor Xa inhibitor darexaban (YM150) is still in the running for use in the lucrative indication of acute coronary syndromes, following safety results from a Phase II trial presented at the European Society of Cardiology meeting on 30 August 2011..